Craig Duvall

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

1. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy. Wang Y, Xie Y, Kilchrist KV, Li J, Duvall CL, Oupický D (2020) ACS Appl Mater Interfaces 12(4): 4308-4322
   › Primary publication · 31939276 (PubMed) · PMC7011569 (PubMed Central)
2. Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction. Vanderburgh J, Hill JL, Gupta MK, Kwakwa KA, Wang SK, Moyer K, Bedingfield SK, Merkel AR, d'Arcy R, Guelcher SA, Rhoades JA, Duvall CL (2020) ACS Nano 14(1): 311-327
   › Primary publication · 31894963 (PubMed) · PMC7216559 (PubMed Central)
3. Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles. Garland KM, Sevimli S, Kilchrist KV, Duvall CL, Cook RS, Wilson JT (2019) Cell Mol Bioeng 12(5): 429-442
   › Primary publication · 31719925 (PubMed) · PMC6816657 (PubMed Central)
4. An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles. Evans BC, Fletcher RB, Kilchrist KV, Dailing EA, Mukalel AJ, Colazo JM, Oliver M, Cheung-Flynn J, Brophy CM, Tierney JW, Isenberg JS, Hankenson KD, Ghimire K, Lander C, Gersbach CA, Duvall CL (2019) Nat Commun 10(1): 5012
   › Primary publication · 31676764 (PubMed) · PMC6825215 (PubMed Central)
5. Optimizing Mannose "Click" Conjugation to Polymeric Nanoparticles for Targeted siRNA Delivery to Human and Murine Macrophages. Glass EB, Masjedi S, Dudzinski SO, Wilson AJ, Duvall CL, Yull FE, Giorgio TD (2019) ACS Omega 4(16): 16756-16767
   › Primary publication · 31646220 (PubMed) · PMC6796989 (PubMed Central)
6. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease. Vanderburgh JP, Kwakwa KA, Werfel TA, Merkel AR, Gupta MK, Johnson RW, Guelcher SA, Duvall CL, Rhoades JA (2019) J Control Release : 257-272
   › Primary publication · 31494183 (PubMed) · PMC7007697 (PubMed Central)
7. Preparation, preliminary pharmacokinetic and brain targeting study of metformin encapsulated W/O/W composite submicron emulsions promoted by borneol. Hong L, Li X, Bao Y, Duvall CL, Zhang C, Chen W, Peng C (2019) Eur J Pharm Sci : 160-166
   › Primary publication · 30914361 (PubMed)
8. Applied Bioengineering in Tissue Reconstruction, Replacement, and Regeneration. Colazo JM, Evans BC, Farinas AF, Al-Kassis S, Duvall CL, Thayer WP (2019) Tissue Eng Part B Rev 25(4): 259-290
   › Primary publication · 30896342 (PubMed) · PMC6686706 (PubMed Central)
9. Rapid changes in the microvascular circulation of skeletal muscle impair insulin delivery during sepsis. Mignemi NA, McClatchey PM, Kilchrist KV, Williams IM, Millis BA, Syring KE, Duvall CL, Wasserman DH, McGuinness OP (2019) Am J Physiol Endocrinol Metab 316(6): E1012-E1023
   › Primary publication · 30860883 (PubMed) · PMC6620574 (PubMed Central)
10. Gal8 Visualization of Endosome Disruption Predicts Carrier-Mediated Biologic Drug Intracellular Bioavailability. Kilchrist KV, Dimobi SC, Jackson MA, Evans BC, Werfel TA, Dailing EA, Bedingfield SK, Kelly IB, Duvall CL (2019) ACS Nano 13(2): 1136-1152
    › Primary publication · 30629431 (PubMed) · PMC6995262 (PubMed Central)
11. Dual carrier-cargo hydrophobization and charge ratio optimization improve the systemic circulation and safety of zwitterionic nano-polyplexes. Jackson MA, Bedingfield SK, Yu F, Stokan ME, Miles RE, Curvino EJ, Hoogenboezem EN, Bonami RH, Patel SS, Kendall PL, Giorgio TD, Duvall CL (2019) Biomaterials : 245-259
    › Primary publication · 30458360 (PubMed) · PMC6534819 (PubMed Central)
12. Poly(Thioketal Urethane) Autograft Extenders in an Intertransverse Process Model of Bone Formation. McGough MAP, Shiels SM, Boller LA, Zienkiewicz KJ, Duvall CL, Wenke JC, Guelcher SA (2019) Tissue Eng Part A 25(13-14): 949-963
    › Primary publication · 30398387 (PubMed) · PMC6648232 (PubMed Central)
13. Drug-Free ROS Sponge Polymeric Microspheres Reduce Tissue Damage from Ischemic and Mechanical Injury. O'Grady KP, Kavanaugh TE, Cho H, Ye H, Gupta MK, Madonna MC, Lee J, O'Brien CM, Skala MC, Hasty KA, Duvall CL (2018) ACS Biomater Sci Eng 4(4): 1251-1264
    › Primary publication · 30349873 (PubMed) · PMC6195321 (PubMed Central)
14. Thermogelling, ABC Triblock Copolymer Platform for Resorbable Hydrogels with Tunable, Degradation-Mediated Drug Release. Gupta MK, Martin JR, Dollinger BR, Hattaway ME, Duvall CL (2017) Adv Funct Mater 27(47)
    › Primary publication · 30349427 (PubMed) · PMC6195316 (PubMed Central)
15. Nanotechnology Enabled Modulation of Signaling Pathways Affects Physiologic Responses in Intact Vascular Tissue. Hocking KM, Evans BC, Komalavilas P, Cheung-Flynn J, Duvall CL, Brophy CM (2019) Tissue Eng Part A 25(5-6): 416-426
    › Primary publication · 30132374 (PubMed) · PMC6450456 (PubMed Central)
16. Harnessing albumin as a carrier for cancer therapies. Hoogenboezem EN, Duvall CL (2018) Adv Drug Deliv Rev : 73-89
    › Primary publication · 30012492 (PubMed) · PMC6200408 (PubMed Central)
17. Excipients for the lyoprotection of MAPKAP kinase 2 inhibitory peptide nano-polyplexes. Mukalel AJ, Evans BC, Kilchrist KV, Dailing EA, Burdette B, Cheung-Flynn J, Brophy CM, Duvall CL (2018) J Control Release : 110-119
    › Primary publication · 29709529 (PubMed) · PMC6157733 (PubMed Central)
18. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL (2018) Cancer Res 78(7): 1845-1858
    › Primary publication · 29358172 (PubMed) · PMC5882532 (PubMed Central)
19. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS (2018) Cell Death Dis 9(2): 21
    › Primary publication · 29343814 (PubMed) · PMC5833697 (PubMed Central)
20. Poly(2-propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles as a targeted antigen delivery system to direct either CD4 or CD8 T cell activation. Yang L, Bracho-Sanchez E, Fernando LP, Lewis JS, Carstens MR, Duvall CL, Keselowsky BG (2017) Bioeng Transl Med 2(2): 202-211
    › Primary publication · 29313030 (PubMed) · PMC5675098 (PubMed Central)
21. Formulation and characterization of poly(propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles for pH-dependent membrane disruption and cytosolic delivery. Fernando LP, Lewis JS, Evans BC, Duvall CL, Keselowsky BG (2018) J Biomed Mater Res A 106(4): 1022-1033
    › Primary publication · 29164777 (PubMed) · PMC5851279 (PubMed Central)
22. Unregulated saphenous vein graft distension decreases tissue viscoelasticity. Wise ES, Hocking KM, Evans BC, Duvall CL, Cheung-Flynn J, Brophy CM (2017) Perfusion 32(6): 489-494
    › Primary publication · 28820033 (PubMed) · PMC5967241 (PubMed Central)
23. Porcine Ischemic Wound-Healing Model for Preclinical Testing of Degradable Biomaterials. Patil P, Martin JR, Sarett SM, Pollins AC, Cardwell NL, Davidson JM, Guelcher SA, Nanney LB, Duvall CL (2017) Tissue Eng Part C Methods 23(11): 754-762
    › Primary publication · 28762881 (PubMed) · PMC5689114 (PubMed Central)
24. Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing. Sarett SM, Werfel TA, Lee L, Jackson MA, Kilchrist KV, Brantley-Sieders D, Duvall CL (2017) Proc Natl Acad Sci U S A 114(32): E6490-E6497
    › Primary publication · 28739942 (PubMed) · PMC5558996 (PubMed Central)
25. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol. Jackson MA, Werfel TA, Curvino EJ, Yu F, Kavanaugh TE, Sarett SM, Dockery MD, Kilchrist KV, Jackson AN, Giorgio TD, Duvall CL (2017) ACS Nano 11(6): 5680-5696
    › Primary publication · 28548843 (PubMed) · PMC5919184 (PubMed Central)
26. Reactive Oxygen Species Shielding Hydrogel for the Delivery of Adherent and Nonadherent Therapeutic Cell Types^. Dollinger BR, Gupta MK, Martin JR, Duvall CL (2017) Tissue Eng Part A 23(19-20): 1120-1131
    › Primary publication · 28394196 (PubMed) · PMC5653132 (PubMed Central)
27. Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo. Werfel TA, Jackson MA, Kavanaugh TE, Kirkbride KC, Miteva M, Giorgio TD, Duvall C (2017) J Control Release : 12-26
    › Primary publication · 28366646 (PubMed) · PMC5484420 (PubMed Central)
28. Oxidatively Degradable Poly(thioketal urethane)/Ceramic Composite Bone Cements with Bone-Like Strength. McEnery MA, Lu S, Gupta MK, Zienkiewicz KJ, Wenke JC, Kalpakci KN, Shimko D, Duvall CL, Guelcher SA (2016) RSC Adv 6(111): 109414-109424
    › Primary publication · 27895899 (PubMed) · PMC5123593 (PubMed Central)
29. Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres. Pasek RC, Kavanaugh TE, Duvall CL, Gannon MA (2016) J Vis Exp (117)
    › Primary publication · 27842374 (PubMed) · PMC5226113 (PubMed Central)
30. Mechanism of Enhanced Cellular Uptake and Cytosolic Retention of MK2 Inhibitory Peptide Nano-polyplexes. Kilchrist KV, Evans BC, Brophy CM, Duvall CL (2016) Cell Mol Bioeng 9(3): 368-381
    › Primary publication · 27818713 (PubMed) · PMC5089375 (PubMed Central)
31. Subfailure Overstretch Injury Leads to Reversible Functional Impairment and Purinergic P2X7 Receptor Activation in Intact Vascular Tissue. Luo W, Guth CM, Jolayemi O, Duvall CL, Brophy CM, Cheung-Flynn J (2016) Front Bioeng Biotechnol : 75
    › Primary publication · 27747211 (PubMed) · PMC5040722 (PubMed Central)
32. Local Delivery of PHD2 siRNA from ROS-Degradable Scaffolds to Promote Diabetic Wound Healing. Martin JR, Nelson CE, Gupta MK, Yu F, Sarett SM, Hocking KM, Pollins AC, Nanney LB, Davidson JM, Guelcher SA, Duvall CL (2016) Adv Healthc Mater 5(21): 2751-2757
    › Primary publication · 27717176 (PubMed) · PMC5152672 (PubMed Central)
33. Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies. Beavers KR, Werfel TA, Shen T, Kavanaugh TE, Kilchrist KV, Mares JW, Fain JS, Wiese CB, Vickers KC, Weiss SM, Duvall CL (2016) Adv Mater 28(36): 7984-7992
    › Primary publication · 27383910 (PubMed) · PMC5152671 (PubMed Central)
34. Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing. Sarett SM, Werfel TA, Chandra I, Jackson MA, Kavanaugh TE, Hattaway ME, Giorgio TD, Duvall CL (2016) Biomaterials : 122-32
    › Primary publication · 27163624 (PubMed) · PMC4894661 (PubMed Central)
35. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL (2016) Biomaterials : 71-80
    › Primary publication · 27043768 (PubMed) · PMC4833621 (PubMed Central)
36. Hydrolytic charge-reversal of PEGylated polyplexes enhances intracellular un-packaging and activity of siRNA. Werfel TA, Swain C, Nelson CE, Kilchrist KV, Evans BC, Miteva M, Duvall CL (2016) J Biomed Mater Res A 104(4): 917-27
    › Primary publication · 26691570 (PubMed) · PMC5517028 (PubMed Central)
37. High conversion of HAuCl4 into gold nanorods: A re-seeding approach. Canonico-May SA, Beavers KR, Melvin MJ, Alkilany AM, Duvall CL, Stone JW (2016) J Colloid Interface Sci : 229-32
    › Primary publication · 26550780 (PubMed)
38. Technologies for controlled, local delivery of siRNA. Sarett SM, Nelson CE, Duvall CL (2015) J Control Release : 94-113
    › Primary publication · 26476177 (PubMed) · PMC4665980 (PubMed Central)
39. Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification. Yuasa M, Mignemi NA, Nyman JS, Duvall CL, Schwartz HS, Okawa A, Yoshii T, Bhattacharjee G, Zhao C, Bible JE, Obremskey WT, Flick MJ, Degen JL, Barnett JV, Cates JM, Schoenecker JG (2015) J Clin Invest 125(9): 3723
    › Primary publication · 26325037 (PubMed) · PMC4588290 (PubMed Central)
40. Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification. Yuasa M, Mignemi NA, Nyman JS, Duvall CL, Schwartz HS, Okawa A, Yoshii T, Bhattacharjee G, Zhao C, Bible JE, Obremskey WT, Flick MJ, Degen JL, Barnett JV, Cates JM, Schoenecker JG (2015) J Clin Invest 125(8): 3117-31
    › Primary publication · 26214526 (PubMed) · PMC4563750 (PubMed Central)
41. Shape-engineered multifunctional porous silicon nanoparticles by direct imprinting. Mares JW, Fain JS, Beavers KR, Duvall CL, Weiss SM (2015) Nanotechnology 26(27): 271001
    › Primary publication · 26081802 (PubMed)
42. MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. Evans BC, Hocking KM, Osgood MJ, Voskresensky I, Dmowska J, Kilchrist KV, Brophy CM, Duvall CL (2015) Sci Transl Med 7(291): 291ra95
    › Primary publication · 26062847 (PubMed) · PMC5371354 (PubMed Central)
43. Endosomolytic Nano-Polyplex Platform Technology for Cytosolic Peptide Delivery To Inhibit Pathological Vasoconstriction. Evans BC, Hocking KM, Kilchrist KV, Wise ES, Brophy CM, Duvall CL (2015) ACS Nano 9(6): 5893-907
    › Primary publication · 26004140 (PubMed) · PMC4482421 (PubMed Central)
44. Particle-based technologies for osteoarthritis detection and therapy. Kavanaugh TE, Werfel TA, Cho H, Hasty KA, Duvall CL (2016) Drug Deliv Transl Res 6(2): 132-47
    › Primary publication · 25990835 (PubMed) · PMC4654703 (PubMed Central)
45. A transient cell-shielding method for viable MSC delivery within hydrophobic scaffolds polymerized in situ. Guo R, Ward CL, Davidson JM, Duvall CL, Wenke JC, Guelcher SA (2015) Biomaterials : 21-33
    › Primary publication · 25907036 (PubMed) · PMC4409667 (PubMed Central)
46. Conjugation of palmitic acid improves potency and longevity of siRNA delivered via endosomolytic polymer nanoparticles. Sarett SM, Kilchrist KV, Miteva M, Duvall CL (2015) J Biomed Mater Res A 103(9): 3107-16
    › Primary publication · 25641816 (PubMed) · PMC4520743 (PubMed Central)
47. Quantifying the vascular response to ischemia with speckle variance optical coherence tomography. Poole KM, McCormack DR, Patil CA, Duvall CL, Skala MC (2014) Biomed Opt Express 5(12): 4118-30
    › Primary publication · 25574425 (PubMed) · PMC4285592 (PubMed Central)
48. MiRNA inhibition in tissue engineering and regenerative medicine. Beavers KR, Nelson CE, Duvall CL (2015) Adv Drug Deliv Rev : 123-37
    › Primary publication · 25553957 (PubMed) · PMC4485980 (PubMed Central)
49. Enhanced Performance of Plasmid DNA Polyplexes Stabilized by a Combination of Core Hydrophobicity and Surface PEGylation. Adolph EJ, Nelson CE, Werfel TA, Guo R, Davidson JM, Guelcher SA, Duvall CL (2014) J Mater Chem B 2(46): 8154-8164
    › Primary publication · 25530856 (PubMed) · PMC4269243 (PubMed Central)
50. ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease. Poole KM, Nelson CE, Joshi RV, Martin JR, Gupta MK, Haws SC, Kavanaugh TE, Skala MC, Duvall CL (2015) Biomaterials : 166-75
    › Primary publication · 25522975 (PubMed) · PMC4274772 (PubMed Central)
51. Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers. Miteva M, Kirkbride KC, Kilchrist KV, Werfel TA, Li H, Nelson CE, Gupta MK, Giorgio TD, Duvall CL (2015) Biomaterials : 97-107
    › Primary publication · 25453977 (PubMed) · PMC5477977 (PubMed Central)
52. Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. Li H, Miteva M, Kirkbride KC, Cheng MJ, Nelson CE, Simpson EM, Gupta MK, Duvall CL, Giorgio TD (2015) Biomacromolecules 16(1): 192-201
    › Primary publication · 25414930 (PubMed) · PMC4294138 (PubMed Central)
53. Future nanomedicine for the diagnosis and treatment of osteoarthritis. Eichaker LR, Cho H, Duvall CL, Werfel TA, Hasty KA (2014) Nanomedicine (Lond) 9(14): 2203-15
    › Primary publication · 25405797 (PubMed) · PMC4962602 (PubMed Central)
54. Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release. Gupta MK, Martin JR, Werfel TA, Shen T, Page JM, Duvall CL (2014) J Am Chem Soc 136(42): 14896-902
    › Primary publication · 25254509 (PubMed)
55. Matrix Metalloproteinase Responsive, Proximity-activated Polymeric Nanoparticles for siRNA Delivery. Li H, Yu SS, Miteva M, Nelson CE, Werfel T, Giorgio TD, Duvall CL (2013) Adv Funct Mater 23(24): 3040-3052
    › Primary publication · 25214828 (PubMed) · PMC4159188 (PubMed Central)
56. In situ synthesis of peptide nucleic acids in porous silicon for drug delivery and biosensing. Beavers KR, Mares JW, Swartz CM, Zhao Y, Weiss SM, Duvall CL (2014) Bioconjug Chem 25(7): 1192-7
    › Primary publication · 24949894 (PubMed) · PMC4103755 (PubMed Central)
57. In vivo imaging of nanoparticle delivery and tumor microvasculature with multimodal optical coherence tomography. Tucker-Schwartz JM, Beavers KR, Sit WW, Shah AT, Duvall CL, Skala MC (2014) Biomed Opt Express 5(6): 1731-43
    › Primary publication · 24940536 (PubMed) · PMC4052907 (PubMed Central)
58. siRNA Delivery from an Injectable Scaffold for Wound Therapy. Nelson CE, Gupta MK, Adolph EJ, Guelcher SA, Duvall CL (2013) Adv Wound Care (New Rochelle) 2(3): 93-99
    › Primary publication · 24527332 (PubMed) · PMC3623593 (PubMed Central)
59. A porous tissue engineering scaffold selectively degraded by cell-generated reactive oxygen species. Martin JR, Gupta MK, Page JM, Yu F, Davidson JM, Guelcher SA, Duvall CL (2014) Biomaterials 35(12): 3766-76
    › Primary publication · 24491510 (PubMed) · PMC3975079 (PubMed Central)
60. Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo. Nelson CE, Kim AJ, Adolph EJ, Gupta MK, Yu F, Hocking KM, Davidson JM, Guelcher SA, Duvall CL (2014) Adv Mater 26(4): 607-14, 506
    › Primary publication · 24338842 (PubMed) · PMC3951880 (PubMed Central)
61. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. Nelson CE, Kintzing JR, Hanna A, Shannon JM, Gupta MK, Duvall CL (2013) ACS Nano 7(10): 8870-80
    › Primary publication · 24041122 (PubMed) · PMC3857137 (PubMed Central)
62. Quantitative optical imaging of vascular response in vivo in a model of peripheral arterial disease. Poole KM, Tucker-Schwartz JM, Sit WW, Walsh AJ, Duvall CL, Skala MC (2013) Am J Physiol Heart Circ Physiol 305(8): H1168-80
    › Primary publication · 23955718 (PubMed) · PMC3798791 (PubMed Central)
63. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. Evans BC, Nelson CE, Yu SS, Beavers KR, Kim AJ, Li H, Nelson HM, Giorgio TD, Duvall CL (2013) J Vis Exp (73): e50166
    › Primary publication · 23524982 (PubMed) · PMC3626231 (PubMed Central)
64. Nanocarriers for dual delivery of doxorubicin and siRNA to overcome multidrug resistance. Sarett SM, Beavers KR, Miteva M, Nelson CE, Duvall CL (2013) Nanomedicine (Lond) 8(3): 329-30
    › Primary publication · 23477333 (PubMed)
65. Dual pH- and temperature-responsive microparticles for protein delivery to ischemic tissues. Joshi RV, Nelson CE, Poole KM, Skala MC, Duvall CL (2013) Acta Biomater 9(5): 6526-34
    › Primary publication · 23402764 (PubMed) · PMC3702271 (PubMed Central)
66. Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, Smith CA, Yull FE, Duvall CL, Giorgio TD (2013) Mol Pharm 10(3): 975-87
    › Primary publication · 23331322 (PubMed) · PMC3595119 (PubMed Central)
67. In vivo photothermal optical coherence tomography of gold nanorod contrast agents. Tucker-Schwartz JM, Meyer TA, Patil CA, Duvall CL, Skala MC (2012) Biomed Opt Express 3(11): 2881-95
    › Primary publication · 23162726 (PubMed) · PMC3493242 (PubMed Central)
68. Ex vivo optical metabolic measurements from cultured tissue reflect in vivo tissue status. Walsh AJ, Poole KM, Duvall CL, Skala MC (2012) J Biomed Opt 17(11): 116015
    › Primary publication · 23117810 (PubMed) · PMC3484268 (PubMed Central)
69. Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate. Berguig GY, Convertine AJ, Shi J, Palanca-Wessels MC, Duvall CL, Pun SH, Press OW, Stayton PS (2012) Mol Pharm 9(12): 3506-14
    › Primary publication · 23075320 (PubMed) · PMC3600396 (PubMed Central)
70. Poly(PS-b-DMA) micelles for reactive oxygen species triggered drug release. Gupta MK, Meyer TA, Nelson CE, Duvall CL (2012) J Control Release 162(3): 591-8
    › Primary publication · 22889714 (PubMed) · PMC3572905 (PubMed Central)
71. Sustained local delivery of siRNA from an injectable scaffold. Nelson CE, Gupta MK, Adolph EJ, Shannon JM, Guelcher SA, Duvall CL (2012) Biomaterials 33(4): 1154-61
    › Primary publication · 22061489 (PubMed) · PMC3232066 (PubMed Central)
72. RAFT-synthesized graft copolymers that enhance pH-dependent membrane destabilization and protein circulation times. Crownover E, Duvall CL, Convertine A, Hoffman AS, Stayton PS (2011) J Control Release 155(2): 167-74
    › Primary publication · 21699931 (PubMed) · PMC3273495 (PubMed Central)
73. Delivery of intracellular-acting biologics in pro-apoptotic therapies. Li H, Nelson CE, Evans BC, Duvall CL (2011) Curr Pharm Des 17(3): 293-319
    › Primary publication · 21348831 (PubMed) · PMC3564970 (PubMed Central)
74. Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS (2010) Bioconjug Chem 21(12): 2205-12
    › Primary publication · 21043513 (PubMed) · PMC3075329 (PubMed Central)
75. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Golub JS, Kim YT, Duvall CL, Bellamkonda RV, Gupta D, Lin AS, Weiss D, Robert Taylor W, Guldberg RE (2010) Am J Physiol Heart Circ Physiol 298(6): H1959-65
    › Primary publication · 20228260 (PubMed) · PMC2886627 (PubMed Central)
76. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Duvall CL, Convertine AJ, Benoit DS, Hoffman AS, Stayton PS (2010) Mol Pharm 7(2): 468-76
    › Primary publication · 19968323 (PubMed) · PMC2849913 (PubMed Central)
77. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. Shen X, Wan C, Ramaswamy G, Mavalli M, Wang Y, Duvall CL, Deng LF, Guldberg RE, Eberhart A, Clemens TL, Gilbert SR (2009) J Orthop Res 27(10): 1298-305
    › Primary publication · 19338032 (PubMed) · PMC3767389 (PubMed Central)
78. Development of a novel endosomolytic diblock copolymer for siRNA delivery. Convertine AJ, Benoit DS, Duvall CL, Hoffman AS, Stayton PS (2009) J Control Release 133(3): 221-9
    › Primary publication · 18973780 (PubMed) · PMC3110267 (PubMed Central)
79. 3D imaging of tissue integration with porous biomaterials. Guldberg RE, Duvall CL, Peister A, Oest ME, Lin AS, Palmer AW, Levenston ME (2008) Biomaterials 29(28): 3757-61
    › Primary publication · 18635260 (PubMed) · PMC2553033 (PubMed Central)
80. The role of osteopontin in recovery from hind limb ischemia. Duvall CL, Weiss D, Robinson ST, Alameddine FM, Guldberg RE, Taylor WR (2008) Arterioscler Thromb Vasc Biol 28(2): 290-5
    › Primary publication · 18006856 (PubMed)
81. Host immune competence and local ischemia affects the functionality of engineered vasculature. Chen RR, Snow JK, Palmer JP, Lin AS, Duvall CL, Guldberg RE, Mooney DJ (2007) Microcirculation 14(2): 77-88
    › Primary publication · 17365663 (PubMed)
82. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE (2007) J Bone Miner Res 22(2): 286-97
    › Primary publication · 17087627 (PubMed)
83. Microcomputed tomography imaging of skeletal development and growth. Guldberg RE, Lin AS, Coleman R, Robertson G, Duvall C (2004) Birth Defects Res C Embryo Today 72(3): 250-9
    › Primary publication · 15495187 (PubMed)
84. Quantitative microcomputed tomography analysis of collateral vessel development after ischemic injury. Duvall CL, Taylor WR, Weiss D, Guldberg RE (2004) Am J Physiol Heart Circ Physiol 287(1): H302-10
    › Primary publication · 15016633 (PubMed)
85. Analyzing bone, blood vessels, and biomaterials with microcomputed tomography. Guldberg RE, Ballock RT, Boyan BD, Duvall CL, Lin AS, Nagaraja S, Oest M, Phillips J, Porter BD, Robertson G, Taylor WR (2003) IEEE Eng Med Biol Mag 22(5): 77-83
    › Primary publication · 14699940 (PubMed)

Keywords & MeSH Terms

MeSH terms are retrieved from PubMed records. Learn more.

Key: MeSH Term Keyword